ResearcherLanzhou University Second HospitalActive in the last 2 years

Guoqing Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-2269-2890; OpenAlex author ID A5132689780. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 2 papers

Papers 2

SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. Co-author DOI 10.1111/cas.70369 ↗
Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications. Co-author DOI 10.1111/jgh.70441 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wence Zhou · 2 shared papers, 2026 · strength 0.70
- Paper Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications. DOI 10.1111/jgh.70441 ↗
- Paper SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. DOI 10.1111/cas.70369 ↗
Weixiong Zhu · 2 shared papers, 2026 · strength 0.70
- Paper Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications. DOI 10.1111/jgh.70441 ↗
- Paper SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. DOI 10.1111/cas.70369 ↗
Haofei Chen · 1 shared paper, 2026 · strength 0.32
- Paper SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. DOI 10.1111/cas.70369 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.